Recent Posts
Connect with:
Tuesday / June 18.
HomemieyecarePresbyopes: Your Biggest Opportunity for Growth

Presbyopes: Your Biggest Opportunity for Growth

The global presbyopic patient population continues to grow significantly, with 25 per cent more people predicted to become presbyopic by the year 2020.1 This powerful trend is also seen in Australia and New Zealand where there are around 6.6 million people aged 45-64.2 This is the fastest growing age group of any demographic and many within it are major users of optometry services. Could these presbyopes present your biggest opportunity yet to grow your practice?

A presbyopic patient can present with many challenges, which, until recently, may have reduced their suitability and ease of fitting with contact lenses.

Challenges included optimum vision being harder to obtain and age-related ocular changes affecting lens comfort. These factors have contributed to only a very small proportion of presbyopes using or being offered contact lenses.

Recent advances in contact lens technology, however, have included the development of innovative new lens materials and designs more suited to the presbyopic patient. This offers enormous scope to increase the number of these patients in your practice who could benefit from occasional or regular contact lens wear.

A streamlined fitting process has been created around this technology, based on eye care professionals’ real-world experience…

The Choice

Not only do your presbyopic patients now have the option of wearing contact lenses specifically created to suit their unique needs, they also have a choice of replacement frequencies.

CooperVision has one of the most comprehensive multifocal contact lens portfolios for presbyopic patients available, offering both monthly and daily lenses using two materials especially appropriate for this age group. There is even a monthly option for presbyopes with astigmatism; Proclear multifocal toric, with over one million parameter variations. Consequently multifocals are becoming a popular choice over monovision for presbyopic patients, both globally and locally, and the total market for these lenses has grown by around 50 per cent in the past two years.3

The Monthly Lens

Biofinity multifocal is a monthly replacement contact lens that provides both comfort and excellent vision. It is created from a unique third generation silicone hydrogel material that has very high oxygen permeability and a low modulus.

As people age, their eyes can become drier, which may affect lens comfort and wearing time. The naturally wettable Biofinity material retains water within the lens, minimising dehydration and is thus an excellent choice for presbyopes.

Biofinity multifocal is an ideal choice for those presbyopic patients who want to
wear contact lenses every day and for
long hours, and who require excellent vision at all times.4

The Daily Lens

CooperVision also offers a daily disposable lens called Proclear 1 day multifocal. This lens appeals to patients who may want to wear their contact lenses occasionally or regularly and require a cost-effective, convenient solution.

Proclear 1 day multifocal lenses provide excellent vision at all distances while remaining comfortable throughout the day for those presbyopic patients who are likely to experience age-related dryness.

PC Technology means Proclear multifocal lenses contain PC (phosphorylcholine) molecules, which are found naturally in human cell membranes. PC molecules attract and surround themselves with water, helping to keep the lenses hydrated. This naturally wettable material means that the lenses have a deposit-resistant surface that also helps maintain the integrity of the tear film.

Proclear is the only contact lens material with the following FDA claim for dry eyes: “may provide comfort for those who experience dryness or mild discomfort during lens wear”.

The Fit

CooperVision’s Biofinity multifocal lenses use Balanced Progressive Technology, so that two different optical designs (D and N) utilise the processing power of the visual cortex to enhance vision. Lens zones are also optimised for each sphere and add power, allowing for an individualised fitting for each wearer and eye.

A streamlined fitting process has been created around this technology, based on eye care professionals’ real-world experience. Fitting lower add powers is now simpler than ever, by using the same
D lens design for both eyes.

Fitting higher add powers continues to be flexible, giving you more options for greater accuracy. An easy to use fitting guide has been created to maximise fitting success with minimum chair time.

Biofinity multifocal is available in sphere powers of +6.00D to -8.00D and in four add powers, +1.00, +1.50, +2.00 and +2.50D, meaning a very high proportion of prescriptions are catered for.

In the case of Proclear 1 day multifocal, the centre-near aspheric design and simplified fitting approach make it easy to manage patients through all stages of presbyopia. These lenses are offered in a broad power range of +6.00D to -10.00D and are designed with a single power profile with all lenses incorporating a low add. When needed, the use of a ‘near boost’ (mild over-plus) in the non-dominant eye means the lens can accommodate patients with up to a +2.50 add while still maintaining binocular vision at all distances.

The Support

The ultimate aim of CooperVision’s multifocal lens technologies and fitting processes is to have patients spend less time in the exam chair with greater likelihood of fitting success, more profitable visits and improved patient satisfaction.

To show just how easy it can be to fit your presbyopic patients with multifocal contact lenses, CooperVision can provide professional and technical support. For further information please contact your

local CooperVision Business Development Manager or call CooperVision Customer Service on FreeCall (AUS)1800 655 480 or (NZ) 0800 606060.

With more presbyopic patients emerging everyday there is tremendous opportunity for practitioners to embrace contact lens wear in this group.


1. Holden BA et al. Archives of Ophthalmology 2008; 126(12): 1731-39

2. Australian Bureau of Statistics and Statistics NZ

3. CLI data

4. CooperVision data on file. Research conducted December 2011.